4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid;(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione | 2046250-64-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid;(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
• CAS: 2046250-64-8
• 化学式: C35H45Cl2NO7
• 分子量: 662.6
• InChiKey: MQXAKIDDTLIPMU-HNGAPHHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.14
• 重原子数：
  45
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT
  申请人：AVEO Pharmaceuticals, Inc.

  公开号：US20170306008A1

  公开（公告）日：2017-10-26

  Methods are provided for improved treatment of subjects with cancer anorexia-cachexia syndrome, comprising treatment with a combination of at least one anti-cancer agent and at least one GDF 15 modulator. Methods are further provided for improved treatment of subjects with anti-cancer agents which induce cachexia, comprising further treating the subject with at least one GDF 15 modulator.